Insider buying · SEC Form 4

LYEL insider buying

Open-market purchases of Lyell Immunopharma, Inc. (LYEL) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.

1insider buy on record
$25.0Mbought in total
1insider
0by CEOs, CFOs and other chiefs
Nov 6, 2026latest scan with a buy

Every recorded buy

ScanInsiderValueSharesAvg priceTypeFiled
Nov 6, 2026ARCH Venture Fund XIII, L.P. / Paul L. BernsDirector / 10% Owner$25.0M2,321,262$10.77AddedNov 5, 2026
Form 4 ↗
Private placement (securities purchase agreement dated Nov 3, 2026) at $10.77/sh. NOT open-market; code P used for direct offerings. LYEL last $15.00 (+39.3% vs placement price — reflects ~28% discount at deal time). ARCH is Lyell's founding VC backer.

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.